Products & Services
News & Features
Join Our Community


All Products & Services

Research Use Only (RUO)

CE-Marked Assays

View all products

Relevant Publications


2014 Product Catalog!

Request our 2014 product catalog


Wall Charts

Request a complimentary copy:

Hematologic Malignancy Testing Algorithm

Clonality Testing Strategy



Notice: Acute Myeloid Leukemia (AML) The FDA has made it clear that a FLT3 companion diagnostic is required for approval of any FLT3-targeted or FLT3-stratified therapy. LabPMM is the only clinical laboratory with access to the patents required to develop and offer a FLT3 companion diagnostic for worldwide use.

Personalized Medicine & IVS
Invivoscribe is a leading provider of clinically-validated CE-marked in vitro diagnostic products. Through our subsidiary, LabPMM, we provide worldwide access to molecular biomarker testing, which enables pharmaceutical companies to bring to the market new targeted treatments, and allows physicians to better determine optimal treatment for their patients.

Research & Biotechnology
Development & Partnering
Companion Diagnostics


LymphoTrack™ Assays for the Ion PGM™ - Now available!

The popular Next-Generation Sequencing-based LymphoTrack™ portfolio has been expanded to include assays for TCRG and IGH on the Ion PGM™. These assays were designed for easy integration into the laboratory workflow, and include a bioinformatics software that allows for simple and streamlined data analysis providing both DNA sequences and frequency distributions of B- and T-cell rearrangements. Contact us for more information.


View a video of our AMP 2013 Workshop!

We have posted a condensed version of our AMP workshop entitled Clonality Testing by Next-Generation Sequencing: Latest Developments from the New Frontier. This talk was given to a capacity audience in Phoenix, AZ in November 2013, and now you can enjoy highlights at your own convenience. Click here to view.



LymphoTrack™ IGH Assay Launched

Invivoscribe has expanded its portfolio of next-generation sequencing (NGS) products with the introduction of the LymphoTrack™ IGH Assay (for MiSeq platform). This assay provides unprecedented levels of information in the form of frequency distributions and DNA sequences of rearranged IGH genes. Click here for more information. Contact us to learn more.


CAP Today

The Feature Story in the May 2013 issue of CAP Today titled: “Molecular clonality testing for lymphoma” highlights the benefits of PCR-based B and T cell clonality assays from Invivoscribe. Click here to view the article.


LabPMM and New York

LabPMM is happy to announce that we have received our New York state clinical lab license. Please contact us with any questions.


Invivoscribe Launches the LymphoTrack™ TCRG Assay - MiSeq

This Next Generation Sequencing (NGS) assay provides data for the study of TCRG clonality and provides the frequency distribution and DNA sequence of rearranged TCRG V-J sequences using the MiSeq platform. Click here for more information. Contact us to learn more.


Invivoscribe Launches Genection, a New Personalized Molecular Medicine Company Delivering Global Access to the Entire Clinically-Actionable Genetic Menu.

Click here to learn more about Genection.


In the News

January 8, 2014

Invivoscribe embraces the value of constant process improvement


July 16, 2013 Marketwired

Invivoscribe FLT3 Method Patent Claims Upheld 


June 19, 2013 Marketwired
Invivoscribe FLT3 Testing Patents Strengthened by Supreme Court Ruling


May 14, 2013 Marketwire
Invivoscribe Prevails in German District Court (FLT3 Patent Infringement Action)


December 5, 2012 Marketwire
Takara Bio Grants Patent License to Invivoscribe Technologies for FLT3-ITD Testing in Japan


December 4, 2012 Marketwire
Invivoscribe Launches Genection, a New Personalized Molecular Medicine Company Delivering Global Access to the Entire Clinically-Actionable Genetic Test Menu


May 15, 2012 USPTO
United States Patent No. 8,178,292 issued on May 15, 2012.  This patent further consolidates our already dominant intellectual property around the detection of FLT3-ITD mutations


Press Releases

February 15, 2011
Invivoscribe Announces Collaboration Agreement to Develop Companion Diagnostic

Our growth continues... and continues...

We doubled space at our San Diego headquarters in 2011, building out two additional suites for cGMP manufacturing and shipping. In April 2012 we expanded into another adjacent suite to secure offices for management personnel. LabPMM LLC expanded into dedicated space San Diego in 2011, and LabPMM GmbH, located in Martinsried, Germany, started the move into our brand new European reference laboratory in September 2011. Personnel were hired and completed training at our San Diego facility, and we anticipate completion of assay validation and the start of clinical testing in 2Q2012.

View all News


 h-fb.gif  h-twitter.gif  h-newsvine.gif  
Invivoscribe Companies






Meetings and Conferences


AMP Logo

November 12, 2014

Corporate Workshop
AMP 2013 Annual Meeting
National Harbor, MD, USA

AMP Logo

November 13-15, 2014
AMP 2013 Annual Meeting
National Harbor, MD, USA


December 6-9, 2014
2014 ASH Annual Meeting and Exposition
Moscone Center, San Francisco, CA, USA


View all Events











web design by specto design